tiprankstipranks
Trending News
More News >
OSE Immunotherapeutics SA (FR:OSE)
:OSE
Advertisement

OSE Immunotherapeutics SA (OSE) AI Stock Analysis

Compare
8 Followers

Top Page

FR:OSE

OSE Immunotherapeutics SA

(Frankfurt:OSE)

Select Model
Select Model
Select Model
Outperform 70 (OpenAI - 4o)
Rating:70Outperform
Price Target:
€8.00
▲(13.64% Upside)
The overall stock score of 70 reflects strong technical indicators and an attractive valuation, offset by concerns over declining revenue and negative free cash flow growth. The company's improvements in profitability and operational efficiency are positive, but future growth depends on reversing the revenue decline and maintaining positive cash flow.

OSE Immunotherapeutics SA (OSE) vs. iShares MSCI France ETF (EWQ)

OSE Immunotherapeutics SA Business Overview & Revenue Model

Company DescriptionOSE Immunotherapeutics SA focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. Its products include Tedopi that is in Phase III clinical stage for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; CoVepiT, a prophylactic vaccine against the SARS-CoV-2 virus; BI 765063, which is in Phase I clinical trial to treat solid tumors; and BiCKI, a novel bispecific checkpoint inhibitor platform, targeting PD-1 and innovative targets to fight primary and secondary resistance mechanisms developed by cancers. The company's products also comprise OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren's Syndrome; FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis; and OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, Boehringer Ingelheim, Servier, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA is headquartered in Nantes, France.
How the Company Makes MoneyOSE Immunotherapeutics generates revenue primarily through a combination of product development partnerships, licensing agreements, and potential future sales of its therapeutic candidates. The company collaborates with pharmaceutical companies and research institutions to co-develop its products, often receiving milestone payments as products progress through clinical trials. Additionally, OSE may receive royalties from partners on future sales of any successfully commercialized therapies. The company also seeks funding through grants and public offerings to support its research and development efforts. Significant partnerships with larger pharmaceutical companies enhance its revenue potential and provide financial backing for its innovative projects.

OSE Immunotherapeutics SA Financial Statement Overview

Summary
OSE Immunotherapeutics SA has shown significant improvements in profitability and operational efficiency, with a positive net profit margin and improved EBIT and EBITDA margins. The reduction in leverage and positive return on equity are positive signs for financial stability. However, declining revenue and negative free cash flow growth pose challenges for future growth and sustainability.
Income Statement
65
Positive
The company has shown significant improvement in its income statement metrics over the years. The gross profit margin remains strong at 100%, indicating efficient cost management. The net profit margin has improved dramatically from negative values to 53.6% in the latest year, showcasing a turnaround in profitability. However, the revenue growth rate is negative, indicating a decline in sales, which is a concern for future growth. The EBIT and EBITDA margins have also improved significantly, reflecting better operational efficiency.
Balance Sheet
60
Neutral
The balance sheet shows a mixed picture. The debt-to-equity ratio has decreased from 2.01 to 0.72, indicating reduced leverage and improved financial stability. Return on equity has turned positive at 58.7%, suggesting effective use of equity to generate profits. However, the equity ratio is not explicitly provided, and the company's total assets have not grown significantly, which could limit future expansion.
Cash Flow
55
Neutral
The cash flow statement indicates challenges in maintaining positive cash flow growth. The free cash flow growth rate is negative, reflecting a decline in cash available for reinvestment. However, the operating cash flow to net income ratio is strong at 2.40, indicating good cash generation relative to net income. The free cash flow to net income ratio is nearly 1, suggesting that most of the net income is being converted into free cash flow.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue69.88M2.23M18.30M26.31M10.42M
Gross Profit69.88M2.23M18.30M26.31M10.42M
EBITDA41.20M-17.50M-13.11M-13.72M-18.24M
Net Income37.45M-23.00M-17.76M-16.85M-16.55M
Balance Sheet
Total Assets123.96M82.05M91.67M101.52M96.85M
Cash, Cash Equivalents and Short-Term Investments16.75M18.67M25.62M33.58M29.37M
Total Debt46.13M45.80M44.79M37.13M19.51M
Total Liabilities60.15M59.08M59.12M53.99M35.61M
Stockholders Equity63.81M22.82M32.55M47.89M61.24M
Cash Flow
Free Cash Flow48.36M-20.00M-18.53M-10.39M-19.76M
Operating Cash Flow48.44M-19.76M-18.25M-9.92M-19.55M
Investing Cash Flow-46.91M-507.00K26.00K-827.00K-504.00K
Financing Cash Flow-3.46M13.32M10.27M14.96M23.58M

OSE Immunotherapeutics SA Technical Analysis

Technical Analysis Sentiment
Positive
Last Price7.04
Price Trends
50DMA
6.18
Positive
100DMA
5.81
Positive
200DMA
6.11
Positive
Market Momentum
MACD
0.11
Negative
RSI
71.63
Negative
STOCH
81.05
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:OSE, the sentiment is Positive. The current price of 7.04 is above the 20-day moving average (MA) of 6.02, above the 50-day MA of 6.18, and above the 200-day MA of 6.11, indicating a bullish trend. The MACD of 0.11 indicates Negative momentum. The RSI at 71.63 is Negative, neither overbought nor oversold. The STOCH value of 81.05 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:OSE.

OSE Immunotherapeutics SA Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Outperform
€161.50M4.1786.78%3037.72%
55
Neutral
€149.61M-4.06-223.43%111.76%-22.45%
51
Neutral
€200.42M-5.42-60.75%327.14%49.02%
49
Neutral
€104.31M-3.71-36.00%10.87%
48
Neutral
€777.39M-22.00103.70%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FR:OSE
OSE Immunotherapeutics SA
7.04
-1.68
-19.23%
IPHYF
Innate Pharma SA
2.00
-0.16
-7.41%
GB:0QAV
Nanobiotix
16.80
12.10
257.45%
GB:0OCQ
Transgene
1.12
0.00
0.00%
CMVLF
Cellectis SA
2.60
0.40
18.18%
DE:RFM
Sensorion SAS
0.33
-0.39
-54.17%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 02, 2025